Drugs / CJRB-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05877430 | Sep 2023 → Jul 2026 overdue | head and neck squamous cell carcinoma, melanoma, metastatic malignant neoplasm, non-small cell lung carcinoma | CJ Bioscience, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CJRB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05877430 ↗ |
| Modality | Other / unclassified | “live biotherapeutic product” NCT05877430 ↗ |